Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

[1]  D. Giugliano,et al.  The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs , 2022, Cardiovascular Diabetology.

[2]  D. Giugliano,et al.  GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs , 2021, Cardiovascular Diabetology.

[3]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. , 2021, The lancet. Diabetes & endocrinology.

[4]  J. Rosenstock,et al.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. , 2021, The New England journal of medicine.

[5]  M. Roncaglioni,et al.  Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts , 2021, Diabetes, obesity & metabolism.

[6]  Zhi-Qing Zhao,et al.  Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels , 2020, Cardiovascular Drugs and Therapy.

[7]  Mochao Xiao,et al.  GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction. , 2020, Chemico-biological interactions.

[8]  R. D. de Boer,et al.  The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction , 2020, Cardiovascular research.

[9]  M. McCarthy,et al.  Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2020, Diabetologia.

[10]  Yawei Shi,et al.  Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling. , 2020, Acta biochimica et biophysica Sinica.

[11]  N. Poulter,et al.  Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. , 2020, Journal of the American College of Cardiology.

[12]  Satoshi Ida,et al.  Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis , 2020, Heart Failure Reviews.

[13]  Lefeng Wang,et al.  Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis , 2020, Cardiovascular Diabetology.

[14]  R. Steele,et al.  Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis , 2019, Statistical methods in medical research.

[15]  Maurice B. Bizino,et al.  Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial , 2019, Journal of magnetic resonance imaging : JMRI.

[16]  Neha J. Pagidipati,et al.  Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. , 2019, Circulation.

[17]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[18]  Wei-Wei Zhang,et al.  Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats , 2019, Drug design, development and therapy.

[19]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[20]  A. Wägner,et al.  Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). , 2019, Diabetes & metabolism.

[21]  D. Giugliano,et al.  Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope , 2019, Diabetes, obesity & metabolism.

[22]  Maurice B. Bizino,et al.  Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial , 2019, Cardiovascular Diabetology.

[23]  D. Giugliano,et al.  Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials , 2019, Endocrine.

[24]  V. Fuster,et al.  Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. , 2019, Journal of the American College of Cardiology.

[25]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[26]  Karen E. Joynt Maddox,et al.  US National Trends in Mortality From Acute Myocardial Infarction and Heart Failure: Policy Success or Failure? , 2018, JAMA cardiology.

[27]  M. Diamant,et al.  Effect of continuous exenatide infusion on cardiac function and peri‐operative glucose control in patients undergoing cardiac surgery: A single‐blind, randomized controlled trial , 2017, Diabetes, obesity & metabolism.

[28]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[29]  J. Jensen,et al.  Effect of exercise combined with glucagon‐like peptide‐1 receptor agonist treatment on cardiac function: A randomized double‐blind placebo‐controlled clinical trial , 2017, Diabetes, obesity & metabolism.

[30]  Xiang Wang,et al.  Effects of liraglutide on hemodynamic parameters in patients with heart failure , 2017, Oncotarget.

[31]  K. Moreau,et al.  Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. , 2017, Journal of diabetes and its complications.

[32]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[33]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[34]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[35]  H. Bøtker,et al.  A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[36]  S. Russell,et al.  Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. , 2016, JACC. Heart failure.

[37]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[38]  D. Dutka,et al.  Glucagon-Like Peptide-1 , 2016, JACC. Basic to translational science.

[39]  F. Tian,et al.  Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction , 2016, Endocrine.

[40]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[41]  Woo-Shik Kim,et al.  Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of Exenatide Myocardial Protection in Revascularization Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[42]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[43]  D. Dutka,et al.  Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease , 2011, Heart.

[44]  J. Holst,et al.  Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. , 2010, American journal of physiology. Heart and circulatory physiology.

[45]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[46]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[47]  R. Shannon,et al.  Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. , 2007, The American journal of cardiology.

[48]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[49]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.